UniProtKB/Swiss-Prot P28068 : Variant p.Asp49Val
HLA class II histocompatibility antigen, DM beta chain
Gene: HLA-DMB
Feedback ?
Variant information
Variant position:
49
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Aspartate (D) to Valine (V) at position 49 (D49V, p.Asp49Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and acidic (D) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
The following alleles of DMB are known: DMB*01:01, DMB*01:02, DMB*01:03, DMB*01:04 (DMB3.4), DMB*01:05, DMB*01:06, and DMB*01:07. The sequence shown is that of DMB*01:03.
Additional information on the polymorphism described.
Variant description:
In allele DMB*01:07.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
49
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
263
The length of the canonical sequence.
Location on the sequence:
CLLDDAGTPKDFTYCISFNK
D LLTCWDPEENKMAPCEFGVL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human CLLDDAGTPKDFTYCISFNKD LLTCWDPEENKMAPCEFGVL
Mouse CVLDDAGTPQDFTYCVSFNKD LLACWDPIVGKIVPCEFGVL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
19 – 263
HLA class II histocompatibility antigen, DM beta chain
Topological domain
19 – 218
Lumenal
Region
19 – 112
Beta-1
Disulfide bond
29 – 97
Disulfide bond
43 – 53
Mutagenesis
49 – 49
D -> K. Decreases the interaction with MHCII and peptide exchange.
Mutagenesis
49 – 49
D -> N. Increases the interaction with MHCII and peptide exchange; when associated with Q-65.
Mutagenesis
65 – 65
E -> Q. Increases the interaction with MHCII and peptide exchange; when associated with N-49.
Mutagenesis
65 – 65
E -> R. Decreases the interaction with MHCII and peptide exchange.
Mutagenesis
69 – 69
L -> D. Decreases the interaction with MHCII and peptide exchange.
Beta strand
49 – 55
Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.